Devanaboyina et al. (52) used therapeutic antibodies including fragments of either the myelin oligodendrocyte glycoprotein (MOG), an antigen in multiple sclerosis, or HER2, a tumor protein (52). The gene discussed is MOG; the disease is neoplasm.